Home › Companies › SLS

SELLAS Life Sciences Group

Market cap $3.90B 203.9M shares (10-Q, Nov 11, 2026) × $19.15 close Nov 17, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. SLS009 AML Ph2 topline4Q 2026SLS009 AML Ph2 topline, 4Q 2026, material
  2. SLS009 Tambiciclib readoutDec 14, 2026SLS009 Tambiciclib readout, Dec 14, 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Capital (as filed)

Cash
$135M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$5.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$138M cash per the update of Oct 28, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on SELLAS Life Sciences Group, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch SELLAS Life Sciences (SLS): Scientific Due Diligence for Lead and Pipeline Products Binary event gamble on GPS Phase 3 REGAL readout with SLS009 as a scientifically stronger backup; watch list given open-label trial risk and near-100% peptide vaccine Phase 3 failure rate.
  2. Hold UPDATE: SELLAS (SLS) - Checking the Boxes on the SLS009 Pivot and Cash Runway SLS009 dosed first patient on schedule and financing risk eliminated; thesis intact while awaiting REGAL binary readout.
  3. Hold UPDATE: SELLAS (SLS) - SEC Filings, Cash Runways, and a Peek at the Mechanism Financial runway confirmed at ~$114M pro-forma cash, SLS009 mechanism strengthening, but REGAL binary readout remains the primary catalyst and the wait continues.
  4. Hold UPDATE: SELLAS (SLS) - Two Events From the Bell REGAL is two events from unblinding with financing risk fully retired; hold into the imminent binary readout.
  5. Watch UPDATE: SELLAS Life Sciences (SLS) - The Stock Doubled, the Arbitration Died, and the Cash Grew Stock doubled with no data while still two events from unblinding; risk/reward has materially worsened for new money, and existing holders should consider position sizing given the coin flip at a doubled price.
  6. Watch UPDATE: SELLAS Life Sciences (SLS) - Three Months, Zero Events REGAL still at 78/80 events after three months with no update; fortress balance sheet intact but readout timing is indefinite and the price has doubled since spring, making the risk/reward worse for new money.
  7. Watch UPDATE: SELLAS Life Sciences (SLS) - Event #80 Is In Event #80 reached triggering database lock with topline guided by year-end; scientific risk fully intact but timeline risk is now gone, and existing holders should size for a coin flip landing within weeks.
  8. Watch UPDATE: SELLAS Life Sciences (SLS) - The Safety Net Gets Measured Full SLS009 Phase 2 data shows 34% ORR across all comers vs. the previously cited 46% headline, confirming the safety net is real but smaller; REGAL binary still decides the stock.
  9. Speculative buy speculative UPDATE: SELLAS Life Sciences (SLS) - The Coin Landed Heads REGAL met its primary OS endpoint (HR 0.59, 24.0 vs 14.7 months) against a robust control arm that addresses the main open-label objection; upgrading to speculative buy pending secondary endpoints and FDA feedback.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (28)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)